Not all leaders are good leaders.Perhaps you’ve lost an important executive or you’re establishing a local leadership team. You know that the leader you choose will have a major impact on the organization. So how can you avoid hiring the…
HOME > COMMENTARY
COMMENTARY
-
< Special Contribution >
January 13, 2003
-
BARKER ON DRUGS
December 23, 2002
-
BARKER ON DRUGS (10)
November 18, 2002
-
BARKER ON DRUGS (9)
October 14, 2002
-
Commentary 2 articles
October 7, 2002
-
Barker on Drugs (8)
September 9, 2002
-
Barkers on Drugs (7)
July 29, 2002
-
BARKER ON DRUGS (6) Great Results, Shame about the Forecasts
June 24, 2002
-
BARKER ON DRUGS(5)
June 3, 2002
-
BARKER ON DRUGS(4)
April 22, 2002
-
Drastically Changing Marketing Strategy - The Best Strategy for Company Differentiation -
April 22, 2002
-
BARKER ON DRUGS (3)
March 11, 2002
-
BARKER ON DRUGS
February 18, 2002
-
Comarketing as a Marketing Strategy Option -1-
January 21, 2002
-
Comarketing as a Marketing Strategy Option -2-
January 21, 2002
-
Barker on Drugs (1)
January 14, 2002
-
Why Foreign-affiliated Companies Cannot Expand Their Market Share in Japan
July 9, 2001
-
< Special Contribution >What Are the Requirements for a Japanese Blockbuster Product? -2-
May 21, 2001
-
< Special Contribution >What Are the Requirements for a Japanese Blockbuster Product? -1-
May 21, 2001
-
Forecasting JapaneseDrug Industry Growth in FY2001
March 26, 2001
ページ
Earlier this month, Health Minister Keizo Takemi called on the top executives of 13 major generic makers to restructure the industry with a product consolidation target of “around five companies per API.” While a variety of restructuring options are conceivable,…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…